Information Provided By:
Fly News Breaks for June 20, 2018
STAA
Jun 20, 2018 | 09:59 EDT
Canaccord analyst Jason Mills raised his price target for STAAR Surgical to $32 from $23 as he believes that with the FDA warning letter resolved, he sees it as primed to take off in the U.S. The analyst views the Warning Letter lift as a bullish catalyst for the stock and the company, with the enormous potential growth engine that is the U.S. market now fully accessible to STAAR. With presbyopia and with full entry into the U.S. market acting as major growth drivers, the analyst expects sustained, double-digit organic growth into the next decade and beyond. He reiterates a Buy rating on the shares.
News For STAA From the Last 2 Days
There are no results for your query STAA